Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications FDA SIDE EFFECTS UPDATE: Kidney Risks Tied to Dehydration From GLP-1 Drugs
Safety updates sourced directly from the FDA's Drug Safety Database, presented in clear and accessible language
July 23, 2025
0 Comments
republishon this page:
Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning these drugs: Byetta, Bydureon BCISE, Mounjaro, Saxenda, Soliqua 100/33, Trulicity, Victoza, and Xultophy 100/3.6.
How to Read This Report
This report is prepared using the most recent information posted in the SrLC database. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.
Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.
Side Effect Update for GLP-1 Receptor Agonists
The FDA is requiring that Glucagon-like peptide-1 (GLP-1) drug labels include updated warnings about the risk of serious kidney injury associated with the drugs’ gastrointestinal effects. Side effects like diarrhea, nausea, and vomiting may cause severe dehydration or “volume depletion,” leading to kidney injury. Some reported cases of kidney injury have required hemodialysis treatment.
Healthcare providers are advised to monitor renal (kidney) function in patients reporting adverse reactions that could lead to severe dehydration, especially when the drug is first started and doses are escalated. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
The FDA also required changes to the labels to achieve a more uniform presentation of side effects and risk information for all of the drugs in the GLP-1 category, including adding or changing subsections for “Acute Pancreatitis” and “Severe Gastrointestinal Adverse Reactions” and revising the “Patient Counseling” section and “Medication Guide.” Some of the labels were also updated with post-marketing reports of hair loss (alopecia) and the neurological symptom of “altered sense of touch,” or dysethesia. Read the revised labels for all changes and additions.
The following safety label changes were made in response to an FDA letter (like this notification letter for Mounjaro) informing drug sponsors of the required warning updates. Ozempic, Rybelsus, Wegovy, and Zepbound were not included in the most recent updates because their labels already included the required safety information. Each treatment listed below is administered by subcutaneous injection (a shot directed at fatty tissue just under the skin) and, unless otherwise specified, is administered weekly.
Byetta (active ingredient: exenatide synthetic) subcutaneous injection; Bydureon BCISE extended-release subcutaneous injection (active ingredient: exenatide synthetic)
Initial FDA Approval: 2005 for Byetta and Bydureon; extended release version approved in 2017
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
The postmarketing experience section now includes reports of dysesthesia (altered sense of touch).
Essential Extras: The original version of Bydureon has been discontinued, but Bydureon BCISE (extended release) remains available and is administered weekly. Byetta is administered twice daily.
FDA Safety Announcements: Bydureon Extended Release Safety Label Change and Revised Label
Byetta FDA Safety Label Change and Byetta Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Mounjaro (active ingredient: tirzepatide) subcutaneous injection
Initial FDA Approval: 2022
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
The postmarketing experience section now includes reports of alopecia (hair loss).
FDA Safety Announcement: Mounjaro FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Saxenda (active ingredient: liraglutide) subcutaneous injection
Initial FDA Approval: 2014 (liraglutide approved in 2010)
Side Effect Update Date: May 28, 2025
Medication Description: For chronic weight management
Updated Side Effects/Safety Information: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).
Essential Extras: This medication is administered once daily.
FDA Safety Announcement: Saxenda FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Soliqua 100/33 (active ingredients: insulin glargine and lixisenatide) subcutaneous injection
Initial FDA Approval: 2016
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).
Essential Extras: This medication is administered once daily.
FDA Safety Announcement: Soliqua FDA Safety Label Change and Revised Drug Label
Trulicity (active ingredient: dulaglutide) subcutaneous injection
Initial FDA Approval: 2014
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
Clinical trial results concerning pancreas-related adverse effects have also been added
The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).
FDA Safety Announcement: Trulicity FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Victoza (active ingredient:liraglutide) subcutaneous injection
Initial FDA Approval: 2010
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
Clinical trial results concerning pancreas-related adverse effects have also been added
The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).
FDA Safety Announcement: Victoza FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Xultophy 100/3.6 (active ingredients: insulin degludec and liraglutide) subcutaneous injection
Initial FDA Approval: 2016
Side Effect Update Date: May 28, 2025
Medication Description: Treats type 2 diabetes
Updated Side Effects/Safety Information: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.
Clinical trial results concerning pancreas-related adverse effects have also been added.
The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).
Essential Extras: This medication is administered once daily.FDA Safety Announcement: Xultophy FDA Safety Label Change and Revised Label
Want to Share Your Story?
If you’ve experienced side effects or medication issues related to this topic, we want to hear from you.
Submit Your Story- Drug Safety-related Labeling Changes (SRLC). (n.d.). FDA.
- Drugs@FDA: FDA-Approved drugs. (n.d.). FDA.
- Research, C. F. D. E. A. (2025, July 11). Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book. U.S. Food And Drug Administration.
- DailyMed. (n.d.).
- Medical Dictionary by Merriam-Webster. (n.d.).
- Lewis, J. L., III. (2024, May 10). Volume depletion. Merck Manual Professional Edition.
- Dialysis – hemodialysis: MedlinePlus Medical Encyclopedia. (n.d.).
- Definition of dysesthesia – NCI Dictionary of Cancer Terms. (n.d.). Cancer.gov.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
on this page:
RECOMMENDED:
DONATE:
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowWe seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
Republish This Story for Free
Creative Commons License (CC BY-NC-ND 4.0)MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
You May Republish Our Articles for Free If:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
You May Not:
- Use our content to promote a product, service, or political candidate
- Republish only part of an article or create derivative works without permission
- Add affiliate links, advertising overlays, or lead generators
- Translate the article without written permission
Contact Us
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
Article HTML
<!-- wp:paragraph -->
<p>Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning these drugs: Byetta, Bydureon BCISE, Mounjaro, Saxenda, Soliqua 100/33, Trulicity, Victoza, and Xultophy 100/3.6.</p>
<!-- /wp:paragraph --><!-- wp:myplugin/custom-alignment-block {"align":"right"} -->
<div class="wp-block-myplugin-custom-alignment-block alignright"><h2>How to Read This Report</h2><p>This report is prepared using the most recent information posted in the <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm" target="_blank" rel="noreferrer noopener">SrLC database</a>. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.<br><br>Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes. </p></div>
<!-- /wp:myplugin/custom-alignment-block --><!-- wp:heading {"level":1} -->
<h1 class="wp-block-heading" id="h-side-effect-update-for-glp-1-receptor-agonists">Side Effect Update for GLP-1 Receptor Agonists</h1>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>The FDA is requiring that Glucagon-like peptide-1 (GLP-1) drug labels include updated warnings about the risk of serious kidney injury associated with the drugs’ gastrointestinal effects. Side effects like diarrhea, nausea, and vomiting may cause severe dehydration or “<a href="https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/fluid-metabolism/volume-depletion" target="_blank" rel="noreferrer noopener">volume depletion</a>,” leading to kidney injury. Some reported cases of kidney injury have required <a href="https://medlineplus.gov/ency/patientinstructions/000707.htm" target="_blank" rel="noreferrer noopener">hemodialysis</a> treatment.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Healthcare providers are advised to monitor renal (kidney) function in patients reporting adverse reactions that could lead to severe dehydration, especially when the drug is first started and doses are escalated. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The FDA also required changes to the labels to achieve a more uniform presentation of side effects and risk information for all of the drugs in the GLP-1 category, including adding or changing subsections for “Acute Pancreatitis” and “Severe Gastrointestinal Adverse Reactions” and revising the “Patient Counseling” section and “Medication Guide.” Some of the labels were also updated with post-marketing reports of hair loss (alopecia) and the neurological symptom of “altered sense of touch,” or <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/dysesthesia" target="_blank" rel="noreferrer noopener">dysethesia</a>. Read the revised labels for all changes and additions.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The following safety label changes were made in response to an FDA letter (like this <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215866Orig1s031ltr.pdf" target="_blank" rel="noreferrer noopener">notification letter</a> for Mounjaro) informing drug sponsors of the required warning updates. Ozempic, Rybelsus, Wegovy, and Zepbound were not included in the most recent updates because their labels already included the required safety information. Each treatment listed below is administered by subcutaneous injection (a shot directed at fatty tissue just under the skin) and, unless otherwise specified, is administered weekly.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-byetta-active-ingredient-exenatide-synthetic-subcutaneous-injection-bydureon-bcise-extended-release-subcutaneous-injection-active-ingredient-exenatide-synthetic">Byetta (active ingredient: exenatide synthetic) subcutaneous injection; Bydureon BCISE extended-release subcutaneous injection (active ingredient: exenatide synthetic)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2005 for Byetta and Bydureon; extended release version approved in 2017</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: The original version of Bydureon has been discontinued, but Bydureon BCISE (extended release) remains available and is administered weekly. Byetta is administered twice daily.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcements</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1872" target="_blank" rel="noreferrer noopener">Bydureon Extended Release Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209210s025lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1809" target="_blank" rel="noreferrer noopener">Byetta FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021773s050lbl.pdf" target="_blank" rel="noreferrer noopener">Byetta Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-mounjaro-active-ingredient-tirzepatide-subcutaneous-injection">Mounjaro (active ingredient: tirzepatide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2022</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2823" target="_blank" rel="noreferrer noopener">Mounjaro FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s010s015s022lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-saxenda-active-ingredient-liraglutide-subcutaneous-injection">Saxenda (active ingredient: liraglutide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2014 (liraglutide approved in 2010)</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: For chronic weight management</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: This medication is administered once daily.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=438" target="_blank" rel="noreferrer noopener">Saxenda FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206321s020lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-soliqua-100-33-active-ingredients-insulin-glargine-and-lixisenatide-subcutaneous-injection">Soliqua 100/33 (active ingredients: insulin glargine and lixisenatide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2016</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras:</strong> This medication is administered once daily.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1245" target="_blank" rel="noreferrer noopener">Soliqua FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208673s018lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-trulicity-active-ingredient-dulaglutide-subcutaneous-injection">Trulicity (active ingredient: dulaglutide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2014</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Clinical trial results concerning pancreas-related adverse effects have also been added</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=816" target="_blank" rel="noreferrer noopener">Trulicity FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125469s061s062lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-victoza-active-ingredient-liraglutide-subcutaneous-injection">Victoza (active ingredient:liraglutide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2010</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Clinical trial results concerning pancreas-related adverse effects have also been added</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=171" target="_blank" rel="noreferrer noopener">Victoza FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-xultophy-100-3-6-active-ingredients-insulin-degludec-and-liraglutide-subcutaneous-injection">Xultophy 100/3.6 (active ingredients: insulin degludec and liraglutide) subcutaneous injection</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2016</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> May 28, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats type 2 diabetes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: A new warning section on “Severe Gastrointestinal Adverse Reactions.” An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting. Signs of potential kidney injury include persistent (or extended) nausea, vomiting, and diarrhea.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Clinical trial results concerning pancreas-related adverse effects have also been added.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The postmarketing experience section now includes reports of alopecia (hair loss) and dysesthesia (altered sense of touch).</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: This medication is administered once daily.FDA Safety Announcement: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=1863" target="_blank" rel="noreferrer noopener">Xultophy FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208583s025lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Label</a></p>
<!-- /wp:paragraph -->